Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial

Lancet

Volumn 357, Issue 9255, 2001, Pages 509-512

  Reid, Ian R ^a   Hague, Wendy ^b   Emberson, Jonathan ^b   Baker, Jennifer ^c   Tonkin, Andrew ^d   Hunt, David ^e   MacMahon, Stephen ^a,b   Sharpe, Norman ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF SYDNEY   (Australia)

^c THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^d NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; PRAVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035901052     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04042-3     Document Type: Article

References (25)

1. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
2. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
3. Nitrogen-containing biphosphonates inhibit the mevalonate pathway and prevent post-translocational prenylation of GTP-binding proteins, including RAS
4. Stimulation of bone formation in vitro and in rodents by statins
5. Statin use, bone mass and fracture: An analysis of two prospective studies
6. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients
7. Oral statin and increased bone mineral density in postmenopausal women
8. HMG-CoA reductase inhibitors and the risk of fractures
9. HMG-CpA reductase inhibitors and the risk of hip fractures in elderly patients
10. Inhibitors of hydroxymethyglutaryl-coenzyme A reductase and risk of fracture among older women
11. Use of statins and risk of fractures
12. Does statin use reduce risk of fracture in postmenopausal women? Results from the Women's Health Initiative Observational Study (WHI-OS)
13. Reliable assessment of the effects of treatment on mortality and major morbidity, I: Clinical trials
14. Reliable assessment of the effects of treatment on mortality and major morbidity, II: Observational studies
15. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
16. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
17. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women: A 5-year randomized trial
18. Randomized trial of oestrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
19. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the fracture intervention trial
20. Prevention of spinal osteoporosis in oophorectomised women
21. Age- and gender-specific rate of fractures in Australia: A population based study
22. Prevalence of insulin resistance in metabolic disorders: The Bruneck Study
23. Role of hyperinsulinemia in atherosclerotic coronary arterial disease: Studies of semi-quantitative coronary angiography
24. Determinants of total body and regional bone mineral density in normal postmenopausal women - A key role for fat mass
25. Circulating insulin levels are related to bone density in normal postmenopausal women